LIPG

Across TCGA pan-cancer cohorts, LIPG mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LIPG data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LIPG mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LIPG expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where LIPG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.426	0.690	.022	17	view →
HNSC	DFS	Quartile	All	0.921	0.581	.038	8	view →
LSCC	DFS	Median	III,IV	0.480	1.000	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LIPG–PDAC (OS)

Open the PDAC breakdown →